Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
19 Focal Segmental Glomerulosclerosis Trials Near You
Power is an online platform that helps thousands of Focal Segmental Glomerulosclerosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerSparsentan for Focal Segmental Glomerulosclerosis
Columbus, Ohio
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:8 - 75
Key Eligibility Criteria
Disqualifiers:Diabetes, Heart Disease, Liver Disease, Others
Must Not Be Taking:Rituximab, Cyclophosphamide, Abatacept
371 Participants Needed
Sparsentan for Proteinuric Kidney Disease
Columbus, Ohio
This trial is testing sparsentan, a daily oral medication, in children with specific kidney diseases that cause high protein levels in urine. The goal is to see if it is safe and effective. Sparsentan helps by reducing protein leakage into the urine, which can protect the kidneys.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:1 - 17
Key Eligibility Criteria
Disqualifiers:Heart Failure, Liver Disease, Malignancy, Others
Must Be Taking:ACEI, ARB
67 Participants Needed
BI 764198 for Focal Segmental Glomerulosclerosis
Columbus, Ohio
This trial tests if the medicine BI 764198 can improve kidney health in adults with a specific kidney disease called FSGS. Participants take the medicine regularly for a few months. Their kidney health is checked through urine samples and regular health check-ups.
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
67 Participants Needed
R3R01 for Alport Syndrome
Columbus, Ohio
This trial tests R3R01, a new drug that lowers fat in kidney cells to improve kidney function and reduce damage. It targets patients with Alport Syndrome and steroid-resistant FSGS who have high protein levels in their urine because their conditions are not improving with current treatments. Another drug has shown promise in reducing protein levels and kidney damage in animal studies.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Hypertension, HIV, Others
Must Be Taking:ACEi, ARB
50 Participants Needed
Plasmapheresis + Rituximab for FSGS
Cincinnati, Ohio
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:1 - 65
Key Eligibility Criteria
Disqualifiers:Genetic FSGS, Secondary FSGS, Infections, Others
Must Not Be Taking:Rituximab
60 Participants Needed
This trial tests a blood-filtering device called the LIPOSORBER® LA-15 System in adults with kidney issues from FSGS who haven't had success with other treatments or have had severe side effects. The device helps by cleaning the blood to protect the kidneys.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:0 - 75
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cardiac Impairments, Infections, Others
Must Not Be Taking:Ace Inhibitors, Arbs, Vitamin K Antagonists
35 Participants Needed
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipidemic condition but the nephrotic condition (e.g, proteinuria and hypoproteinemia).
Although the definitive mechanism by which the system may relieve nephrotic syndrome is unknown, it has been recognized as one of alternative therapies for refractory nephrotic syndrome including focal segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology.
This study is conducted as a post approval study imposed by Humanitarian Device Exemption (HDE) order to confirm the safety and efficacy of the Liposorber® LA-15 System in the treatment of drug-resistant pediatric primary FSGS.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:< 21
Key Eligibility Criteria
Disqualifiers:Age > 21, Pregnancy, Cardiac Impairments, Others
Must Not Be Taking:Ace Inhibitors, Arbs, Vitamin K Antagonists
35 Participants Needed
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).
The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years.
Study details for each participant include:
The study duration will be up to 76 weeks. The treatment duration will be 24 weeks. There will be up to 18 visits.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:16 - 75
Key Eligibility Criteria
Disqualifiers:Genetic FSGS, Secondary MCD, ESKD, Others
Must Be Taking:RAAS Inhibitors, SGLT2 Inhibitors
84 Participants Needed
DMX-200 for Focal Segmental Glomerulosclerosis
Evanston, Illinois
This trial is testing DMX-200, a drug designed to reduce inflammation by blocking signals that attract immune cells. It targets adult patients with a specific kidney disease called FSGS. The drug works by preventing immune cells from gathering in the kidneys, which may help slow down the disease.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 80
Key Eligibility Criteria
Disqualifiers:Diabetes, Malignancy, Heart Failure, Others
Must Be Taking:ARBs
286 Participants Needed
Atrasentan for Kidney Disease
Hinsdale, Illinois
This trial is testing a pill called atrasentan that may help people with certain kidney diseases by reducing harmful protein levels in their urine. It targets patients whose kidney function is getting worse despite standard treatments. The goal is to see if this medication can protect their kidneys.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other CKD, Transplant, Hypertension, Heart Failure, Malignancy, Others
Must Be Taking:RAS Inhibitors, SGLT2 Inhibitors
103 Participants Needed
ManNAc for FSGS
Bethesda, Maryland
Background:
Focal segmental glomerulosclerosis (FSGS) is a disease that causes scarring in parts of the kidneys that filter waste. This can lead to protein loss in the urine, which can worsen kidney function. The kidneys may fail over time, and dialysis or a kidney transplant may be needed. Other treatments for this disease do not always work and often have adverse effects. Better treatments for FSGS are needed.
Objective:
To test a study drug (ManNAc) in people with FSGS.
Eligibility:
People aged 18 years and older with FSGS.
Design:
Participants will have 6 to 7 clinic visits over 14 weeks. Two of the visits will require overnight stays for 2 or 3 nights.
ManNAc is a white powder that comes in a sachet. It is dissolved in water and taken twice a day by mouth. Participants will take their first dose at the clinic. They will learn how to store ManNAc and prepare each dose. They will record their doses in a diary. They will also write down any adverse effects or troubles they have using the drug at home.
During clinic visits, participants will have physical exams with blood and urine tests. They will complete questionnaires about their health, sleep habits, and fatigue symptoms.
During overnight visits, participants will also have 24-hour urine collection.
A study team member will call participants 1 week after the first dose to check on their health. Follow-up phone calls will then be every 2 weeks after each clinic visit.
Participants may meet with a dietitian to discuss nutrition while taking the ManNAc.
Participants may choose to have genetic tests.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Uncontrolled Nephrotic Syndrome, Uncontrolled Hypertension, Active Infection, Diabetes, Others
Must Not Be Taking:Interferons, Lithium, Androgenic Steroids, Others
30 Participants Needed
Reduced-Dose Steroids for Nephrotic Syndrome
Toronto, Ontario
This is a pilot feasibility study for a proposed full-scale randomized controlled trial to evaluate the effectiveness and safety of a reduced-dose oral prednisone (steroids) regimen to treat childhood steroid-sensitive nephrotic syndrome relapses versus standard-dose prednisone (i.e., usual standard of care).
This internal pilot study is a single-center, open-label, randomized controlled trial at The Hospital for Sick Children (Toronto, ON, Canada). The primary objective of this pilot study is to determine the feasibility, safety, and resources needed to conduct the future full-scale randomized controlled trial.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:1 - 18
Key Eligibility Criteria
Disqualifiers:Steroid-resistant Nephrotic Syndrome, Others
Must Be Taking:Prednisone
50 Participants Needed
Baricitinib for Chronic Kidney Disease
Durham, North Carolina
This trial is testing if baricitinib can safely reduce high levels of albumin in the urine for African American/Blacks with certain kidney conditions. The drug works by reducing inflammation in the kidneys. Baricitinib has been previously tested for its effectiveness in reducing albumin in adults with Type 2 diabetes who are at high risk for worsening kidney disease.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, HIV, Sickle Cell, Others
Must Be Taking:Antihypertensives
75 Participants Needed
taVNS for Nephrotic Syndrome in Children
Philadelphia, Pennsylvania
This trial tests a new treatment for children with frequently relapsing nephrotic syndrome using a device that sends gentle electrical pulses to the ear. The goal is to see if this method can safely help manage their condition by reducing inflammation through nerve stimulation.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:3 - 17
Key Eligibility Criteria
Disqualifiers:Secondary Nephrotic Syndrome, Cardiac Disease, Others
Must Not Be Taking:Steroids, Immunosuppressants
30 Participants Needed
Vagus Nerve Stimulation for Nephrotic Syndrome
Philadelphia, Pennsylvania
Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated noninvasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:3 - 17
Key Eligibility Criteria
Disqualifiers:Genetic Defects, Cardiac Disease, Others
Must Be Taking:Immunosuppressants, ACE Inhibitors
10 Participants Needed
Metformin for FSGS
New York, New York
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Liver Disease, Diabetes, Dementia, Others
Must Be Taking:Glucocorticoids
30 Participants Needed
Obinutuzumab for Focal Segmental Glomerulosclerosis
Rochester, Minnesota
This trial is testing a medication called Obinutuzumab to see if it can help reduce protein levels in the urine of patients with kidney problems. The medication works by helping the immune system target and attack harmful cells. The goal is to find out if it is safe and effective for these patients.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Genetic FSGS, Hepatitis, HIV, Others
Must Not Be Taking:Cyclophosphamide
20 Participants Needed
WAL0921 for Kidney Disease
Tamarac, Florida
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Organ Transplant, Substance Use, Others
96 Participants Needed
Stem Cell + Kidney Transplant for Renal Disease
Palo Alto, California
This trial tests a special stem cell transplant followed by a kidney transplant in patients who need a new kidney. The goal is to prevent kidney rejection without lifelong medication by preparing the immune system to accept the new kidney.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:1 - 30
Key Eligibility Criteria
Disqualifiers:Pregnancy, Severe Cardiovascular Disease, Others
12 Participants Needed
Why Other Patients Applied
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Focal Segmental Glomerulosclerosis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do Focal Segmental Glomerulosclerosis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Focal Segmental Glomerulosclerosis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Focal Segmental Glomerulosclerosis is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a Focal Segmental Glomerulosclerosis medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest Focal Segmental Glomerulosclerosis clinical trials ?
Most recently, we added ManNAc for FSGS, Multiple Drugs for Focal Segmental Glomerulosclerosis and Minimal Change Disease and Reduced-Dose Steroids for Nephrotic Syndrome to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.